Science-Driven. Strategy-Led.
Renaistre Scientific was built on the conviction that exceptional science and rigorous strategy are inseparable. We partner with biotech and pharma companies across the full development arc — from preclinical pharmacology and AI-augmented drug discovery to business development, scientific operations, and commercial organization — delivering the expertise needed to move programs forward with confidence.
Born from the Bench. Built for the Boardroom.
Renaistre Scientific was founded after more than two decades at the intersection of drug discovery, development, and commercial strategy. Having worked across early-stage biotechs, large pharma organizations, and academic research institutions, the gaps were clear: too many promising programs stall not because the science fails, but because the strategy, operations, or partnerships aren't built to match.
The name Renaistre — drawn from the French word for rebirth — reflects a core belief: that programs which have stalled, struggled, or simply never had the right support deserve a chance to be reborn. Whether that means sharper preclinical data, smarter use of AI, a stronger CRO network, a better-structured deal, or the commercial infrastructure to bring an asset to market, we provide the expertise to move it forward.
Today, Renaistre Scientific works with biotech and pharma companies at every stage of the development arc — bringing deep scientific expertise, AI-augmented strategy, hands-on operational support, and commercial acumen to every engagement.
"Science is our passion — and humanity is our purpose. Through expert consultative services across life sciences and biomedical research, we exist to help the people and programs advancing human health move faster, think clearer, and reach further than they could alone."
Scientific Integrity
Every recommendation is grounded in evidence. We don't cut corners on the science — because your investors, partners, and above all, humanity, are counting on it.
Strategic Clarity
Complex problems deserve clear answers. We translate scientific nuance into actionable strategy that your whole organization can execute against.
Operational Rigor
Good intentions don't move programs forward — disciplined execution does. We help ensure the systems, oversight, and accountability are in place to keep your program on track.
Long-Term Partnership
We invest in you and your successes, not just the engagement. Our goal is to be the trusted advisor you return to at every inflection point.
Founder & Principal Consultant
Adam C. Mathias
With over 20 years of global cancer drug discovery experience within the preclinical CRO industry, our founder has supported hundreds of oncology drug development programs across numerous cancer indications and therapeutic modalities — driven by both traditional and cutting-edge AI-based strategies. That expertise spans the full spectrum: scientific leadership of a cancer research division, pharmaceutical manufacturing regulatory compliance and quality assurance in Asia, and operational, commercial and business development roles at some of the most respected organizations in the preclinical space, including Charles River Discovery, Eurofins, Crown Bioscience, and Champions Oncology. Over the course of that career, our founder directed and executed tens of thousands of preclinical translational pharmacology studies across oncology, metabolic disease, cardiovascular disease, and inflammation — and contributed to the R&D programs behind 35 FDA-approved cancer therapeutics, including Kadcyla, Opdivo, Tagrisso, and Daraxonrasib. On the commercial side, multiple multi-year, multi-million-dollar strategic partnerships were forged with leading Pharma and biotech companies. That track record — built on a vested, consultative, and transparent approach — is the foundation on which Renaistre Scientific was built.
- 20+ years in global cancer drug discovery and preclinical CRO leadership
- Contributions to 35 FDA-approved cancer therapeutic R&D programs
- Preclinical translational pharmacology across oncology, metabolic, cardiovascular, and inflammatory disease
- Scientific and operational leadership of a preclinical cancer research organization
- AI-based drug development strategy and platform evaluation
- Multi-million-dollar strategic partnership development with global pharma and biotech
- Business development across regional, national, and global markets
- GMP regulatory compliance, quality assurance, and API Drug Master File management
- Pharmaceutical manufacturing oversight and supply chain management in Asia
- PDX program establishment and innovative in vivo model development
Ready to Work Together?
Whether you need a strategic partner for a single program milestone or ongoing advisory support, we'd welcome the conversation.